Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report

Informations

• Publié par: reportstack-com
• Nombre de lectures: 15
• Langue: English

Extrait

Global Neuroendocrine Carcinoma

Therapeutics Market To Reach $475m By 2019 -

Report

PR Newswire

NEW YORK, LONDON, BERLIN and PARIS, July 2, 2012

NEW YORK

,

LONDON

,

BERLIN

and

PARIS

,

July 2, 2012

/PRNewswire/ --

The global Neuroendocrine carcinoma therapeutics market was worth

$127m

in 2011 and now the market is forecast to grow at Compound Annual Growth

Rate (CAGR) of 17.9% to reach

$475m

by 2019. The high growth is primarily

attributed to the advent of approved drugs, Sutent (sunitinib) and Afinitor

(everolimus), in the major markets. The expected launch of promising drugs in

the forecast period will drive the market. The promising drugs to be launched

include: Avastin (bevacizumab) and Lutathera ([177Lutetium]-DOTA0-Tyr3-

Octreotate) for Gastrointestinal (GI) carcinoid and pancreatic Neuroendocrine

Tumors (NETs), pasireotide (SOM 230), and Somatuline (lanreotide acetate)

Autogel/Depot for GI carcinoids NETs. These factors will accelerate the growth

of the neuroendocrine carcinoma therapeutics market.

Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market

Forecast to 2019 report is an essential source of information and analysis on

the global Neuroendocrine carcinoma market. The report identifies the key

trends shaping and driving the market. It also provides insights on the prevalent

competitive landscape and the emerging players that are expected to

significantly alter the positioning of the current market leaders. Most

importantly, the report provides valuable insights on the pipeline products in

the global Neuroendocrine carcinoma sector.

Scope of the research:

- Annualized data on the seven key Neuroendocrine carcinoma markets

revenue data (the US,

France

,

Germany

,

Italy

,

Spain

, the UK and

Japan

) from

2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data showing a split across the different phases, mechanisms

of action being developed and emerging trends in the market. Pipeline

candidates fall under the following mechanisms of action: Somatostatin

analogues and Vascular Endothelial Growth Factor (VEGF) inhibitors, insulin-like

growth factor-1 receptor (IGFR-1) inhibitors, tyrosine kinase inhibitor (TKI) and

Smoothened (Smo) inhibitor.

- Analysis of the current and future competition in the global Neuroendocrine

carcinoma market. Key market players covered are Novartis AG, Roche, the Eli

Lilly & Company, Callisto Pharmaceuticals, Molecular Insight pharmaceuticals,

Advanced Accelerator Applications S.A, Roche, Ipsen and Amgen Inc.

- Insightful review of the key drivers, restraints and challenges in the

Neuroendocrine Carcinoma Therapeutics Market . Each trend is independently

researched to provide a qualitative analysis of its implications.

- Key topics covered include a strategic competitor assessment, market

characterization, and unmet needs and their implications for the

Neuroendocrine carcinoma therapeutics market.

- Analysis of key recent licensing and partnership agreements in the

Neuroendocrine carcinoma market.

To view the detailed table of contents for this report please click -

Neuroendocrine Carcinoma Therapeutics Market Report or visit

http://www.reportstack.com

Other Pipeline Assessment and Market Forecast Reports:

Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics Market Report

Osteoarthritis Pain Therapeutics market report

Gastrointestinal Stromal Tumors Therapeutics report

Retinal Vein Occlusion Therapeutics Pipeline Assessment

Chronic Urticaria or Hives Therapeutics Pipeline Assessment and Market

Forecast

Myelofibrosis Therapeutics Market Report

Nasopharyngeal Cancer Therapeutics - Pipeline Assessment

Laryngeal Cancer Therapeutics - Pipeline Assessment Report

Pulmonary Embolism Therapeutics - Pipeline Assessment

Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts

Clostridium difficile Infection Therapeutics - Pipeline Assessment report

Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts

Waldenstrom's Macroglobulinemia Therapeutics - Pipeline Assessment report

Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis

2020

Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to

2018

About Reportstack™ :

Reportstack.com is one of the leading distributors of market research reports in

the world today. Reportstack hosts more than 150,000 research products from

the world's top publication houses. These publications are distributed amongst

12 top industry verticals and 62 sub verticals, which are then further classified

into 257 business categories and 5000 micro markets. The vast selection

criterion provides granular data from the length and breadth of all industries

delivering Reportstack.com members with cutting edge research products to

facilitate strategic business decisions. Reportstack.com provides access to over

50,000 company profiles and their strategic information like deals and

partnerships analysis, SWOT analysis reports, merger & acquisition activity

analysis and new product launches. Reportstack.com is also a leader in the field

of Oncology Market Research Reports and Medical Devices Pipeline Analysis.

Contact Reportstack.com:

Nathan Gold

Phone: [phone]

Email: [e-mail]

Twitter: http://twitter.com/#!/reportstack

Facebook: http://www.facebook.com/pages/Reportstack/182382778485635

Blogs: Cancer Research Reports

Oncology Market Research Reports